HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Clinical trials for HR POSITIVE/HER-2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR POSITIVE/HER-2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HR POSITIVE/HER-2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancers with PIK3CA mutation
Disease control Recruiting nowThis early-phase study tests an experimental drug called CGT6297 in about 90 adults whose advanced solid tumors (including certain breast and endometrial cancers) have a specific genetic change called PIK3CA. The main goals are to find a safe dose and see if the drug can shrink o…
Matched conditions: HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
Blood test may spot hidden breast cancer cells before they return
Knowledge-focused Recruiting nowThis study is for 900 people with breast cancer who have finished their main treatment. It uses a blood test to look for tiny bits of cancer DNA, called ctDNA, that might still be in the body. The goal is to see if this test can help predict if the cancer will come back and help …
Matched conditions: HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:04 UTC